Floatz logo

7-ISOPROPOXYISOFLAVONE

Subjective Cognitive Decline (SCD)

Massachusetts General HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Subjective Cognitive Decline (SCD) cohort.

Asset / SponsorPhaseRating
PARTHENOLIDE (CONSTITUENT OF FEVERFEW)
Massachusetts General Hospital
Phase 2CCC

Same molecule, other indications

7-ISOPROPOXYISOFLAVONE is also rated in:

Mild Cognitive Impairment (MCI)Dormant
CCC
Indicative ·
53 / 100
View asset →
Alzheimer DiseaseDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →